• 1
    Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441: 431-436.
  • 2
    Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007; 13: 3423-3430.
  • 3
    Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006; 66: 3859-3868.
  • 4
    Liu GH, Wang SR, Wang B, Kong BH. Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer. 2006; 16: 1777-1782.
  • 5
    Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT, Sarkar FH. Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB [serial online]. J Ovarian Res. 2008; 1: 9.
  • 6
    Brown M, Cohen J, Arun P, Chen Z, Van Waes C. NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets. 2008; 12: 1109-1122.
  • 7
    Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol. 2005; 23: 5943-5949.
  • 8
    Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006; 25: 6817-6830.
  • 9
    Yan C, Wang H, Aggarwal B, Boyd DD. A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NF-kappaB motif drives the transition from a repressed to an activated state of gene expression. FASEB J. 2004; 18: 540-541.
  • 10
    Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res. 2008; 6: 525-534.
  • 11
    Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006; 12: 939-944.
  • 12
    Sarosy GA, Hussain MM, Seiden MV, et al. Ten-year follow up of a phase 2 study of does-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced stage epithelial ovarian cancer. Cancer. 2010; 116: 1476-1484
  • 13
    Hussain MM, Seiden MV, Fuller A, et al. A two institution phase II study of paclitaxel (T), cyclophosphamide (C), cisplatin (P) with G-CSF (G) for patients with newly diagnosed advanced stage ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2002; 21. Abstract 813.
  • 14
    Kohn EC, Sarosy GA, Davis P, et al. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol. 1996; 62: 181-191.
  • 15
    Hollander M, Wolfe D. Nonparametrical Statistical Methods. 2nd ed. New York: John Wiley & Sons, Inc.; 1999.
  • 16
    Agresti A. Categorical Data Analysis. New York: John Wiley & Sons, Inc.; 1990.
  • 17
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 18
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chem Rep. 1966; 50: 163-170.
  • 19
    Cox D. Regression models and life tables. J R Stat Soc. 1972; 34: 187-202.
  • 20
    Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439: 353-357.
  • 21
    Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008; 68: 5478-5486.
  • 22
    Annunziata CM, Kleinberg L, Davidson B, et al. BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res. 2007; 13( 22 pt 1): 6585-6592.
  • 23
    Slipicevic A, Oy GF, Askildt IC, et al. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol. 2009; 40: 527-537.
  • 24
    Sillanpaa S, Anttila M, Voutilainen K, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol. 2007; 104: 296-303.
  • 25
    Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007; 6: 11.
  • 26
    Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther. 2008; 7: 3441-3451.
  • 27
    Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25: 9-34.
  • 28
    Saccani A, Schioppa T, Porta C, et al. p50 Nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006; 66: 11432-11440.